As Goes Biogen So Follows The Biotech Industry
The catalyst for the newfound enthusiasm is data presented on Biogen's lead compound Aducanumab for the treatment of Alzheimer's disease. Biogen continues its streak of market moving events in the biotech space for 2016.
from Biotech News
0 Comments